Evidence map›Paper›PMID 42638380›Full record

ArticleCurrent organic synthesis2026

Sustainable Synthesis of Aryl Pyrano-bis-coumarin and Dibenzo[a,j] xanthene Derivatives Using Organocatalyst Triethanol Ammonium Salt (tris (2-hydroxyl) Ammonium 2-(1,1-dioxido-3-oxobenzo[d]isothiazol- 2(3H)-yl) acetate) Under Microwave Irradiation.

Elahe Hadadianpour, Behjat Pouramiri

Abstract read
PubMed Publisher
In one paragraph

Article in Current organic synthesis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Elahe HadadianpourDepartment of Chemistry and Biochemistry, Texas Tech University, Lubbock, TX 79409, United States.
Behjat PouramiriDepartment of Chemistry, Qom University of Technology, Qom, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionRecently, there has been a noticeable growth in the application of organocatalysts for the green synthesis of various organic molecules. Organocatalysts are efficient and sustainable agents for promoting chemical reactions in solvent-free conditions. In this study, a new triethanolammonium-based organocatalyst, tris(2-hydroxyethyl)ammonium 2-(1,1-dioxido-3- oxobenzo[d]isothiazol-2(3H)-yl) acetate, was efficiently designed and synthesized through a simple and environmentally benign procedure.

methodsThis organosalt was subsequently employed as a novel green catalyst for the synthesis of a wide range of aryl bis-coumarin (3a-j) and dibenzo[a,j]xanthene (5a-j) derivatives under solventfree conditions and microwave irradiation.

resultsThe structures of the synthesized ionic liquid catalyst and heterocyclic products were fully characterized by NMR and IR spectroscopy, and the obtained spectral data were consistent with previously reported values for the corresponding compounds. Furthermore, various reaction parameters, including solvent, temperature, reaction time, and synthetic method, were systematically optimized to achieve the best operational conditions. DISCUSSION: In this study, various conditions, including solvent, temperature, time, and method of synthesis, were evaluated to determine the optimal synthesis conditions.

conclusionOverall, this work introduces an efficient, sustainable, and operationally straightforward catalytic system for the green synthesis of biologically important heterocyclic molecules.

Indexed as

Bis-coumarinDibenzo[agreen chemistryionic liquidsj]xanthenemicrowave irradiationorganocatalystsolvent- free synthesis

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.